.Attributes Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint asks for incorporation of people with MASLD and dimension of liver end results in cardio-- renal-- metabolic trials, when information advise mechanistically conceivable advantages as well as clinical security-- and also details considerations for test layout as well as regulatory commendation.